GILD.BA is trading 4.5% down today at $50,850, as broader market weakness and profit-taking outweigh a significant analyst upgrade.
- HSBC upgraded Gilead Sciences from Hold to Buy and raised its price target from $133 to $155, citing strength in its HIV and oncology franchises.
- The stock is facing downward pressure alongside major U.S. indices, suggesting that macro sentiment is currently offsetting the positive fundamental news.